For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ORGANIZATION
ORGANIZATION
- Expand Self-Medication Tax Break to Cover All Non-Prescription Drugs: OTC Group
July 6, 2020
- Stop Patient Enrollment in Avigan Studies: Drug Damage Watchdog
July 3, 2020
- Drug Makers Joining Forces to Share Manufacturing Capacities, Accelerate COVID-19 Programs: PhRMA CMO
July 2, 2020
- COVID-19 Having “Serious Impact” on New Drug Development; JPMA Calls for Strong Systems for Emergencies
July 2, 2020
- Generic Use Rate at 76.9% in FY2019, 78.5% in Jan.-March 2020: JGA
July 1, 2020
- Toshio Nakagawa Elected as New Chief of Japan Medical Association
June 29, 2020
- JPMA to Govt: Build Japanese CDC to Run Infectious Disease Measures, Pandemics Will Certainly Hit Again
June 18, 2020
- It’s Not the Right Time to Conduct Drug Price Survey for Off-Year Re-Pricing: JPMA Chief
June 18, 2020
- Japan Biotech Group Submits Request to Health Minister on Coronavirus-Tied Development
June 17, 2020
- Nearly 80% of Clinics See Increase in Long-Term Prescriptions amid COVID-19: JMA Survey
June 15, 2020
- Opinion Reflected to Certain Degree for Comparator PMP Deduction Rule: FPMAJ
June 12, 2020
- Impact of Off-Year Drug Re-Pricing Should Be Limited: FPMAJ
June 12, 2020
- Eisai’s Akana Elected as New Chair of FPMAJ’s Drug Pricing Committee
June 12, 2020
- New Special Rule for “Indication Change” Re-Pricing Significantly Lacks Predictability: FPMAJ
June 12, 2020
- 3 Healthcare Organizations Prod Govt to Forgo FY2020 Drug Price Survey
June 11, 2020
- Postpone Off-Year Drug Re-Pricing Until 2023 or Beyond: JPMA
June 11, 2020
- Daiichi Sankyo CEO Manabe Set to Gain Lobbying Experience as FPMAJ Vice Chair, Chairman Seat Eyed for 2021
June 10, 2020
- Japan Pharma Trade Group Nudges Govt to Postpone Off-Year Re-Pricing
June 8, 2020
- Patient Advocacy Group Urges MLHW to Increase Funding for Pancreatic Cancer Research
June 8, 2020
- API/Intermediate Imports from India Still Stalled, Traders’ Group Calls for Govt Schemes
June 4, 2020
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…